Arranta Bio

Watertown, United States Founded: 2019 • Age: 7 yrs Acquired By Recipharm
Developer of therapeutics for microbiome based diseases
Annual revenue - Latest available
Total funding $82.0M 1 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Arranta Bio

Arranta Bio is a company based in Watertown (United States) founded in 2019 was acquired by Recipharm in February 2022. Arranta Bio has raised $82 million across 1 funding round from investors including Thermo Fisher Scientific, Recipharm and Ampersand Capital Partners. Arranta Bio has completed 1 acquisition, including Captozyme. Arranta Bio operates in a competitive market with competitors including KBI Biopharma, Aldevron, Kemwell Biopharma, Eurogentec and Ovagen, among others.

  • Headquarter Watertown, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $82 M (USD)

    in 1 rounds

  • Latest Funding Round
    $82 M (USD), Series C

    Oct 30, 2019

  • Investors
  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    Recipharm

    (Feb 27, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Arranta Bio

Headcount 50-200
Employee Profiles 48
Board Members and Advisors 8
Employee Profiles
People
Amanda Victorious
Bioassay Scientist, Analytical Development
People
Julian Coles
Associate Scientist I | Microbiome Process Development
People
Brandon Morris
Accounting Assistant
People
Steve Favaloro
Chief Financial Officer

Unlock access to complete

Board Members and Advisors
people
David Q. Anderson
Board Member
people
Joy Cavagnaro
Scientific Advisor
people
Russ Middaugh
Scientific Advisor
people
Shailesh Maingi
Board Member

Unlock access to complete

Funding Insights of Arranta Bio

Arranta Bio has successfully raised a total of $82M through 1 strategic funding round. The most recent funding activity was a Series C round of $82 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Arranta Bio

Arranta Bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Recipharm and Ampersand Capital Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
Locked Locked Locked
Electron microscopy services and microanalysis instruments are provided.
Locked Locked Locked
Pharmaceutical development and manufacturing services are offered contractually.
Locked Locked Locked
Premium access

Investor details for Arranta Bio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Arranta Bio

Arranta Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Captozyme.

Investments
Premium access

Investment portfolio details for Arranta Bio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Enzyme-based products for kidney stones and hyperoxaluria are developed.
Locked Locked 2009 Locked
Premium access

Complete acquisition details for Arranta Bio

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Arranta Bio

Premium access

Detailed financials for Arranta Bio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Arranta Bio Comparisons

Arranta Bio Primary company
Description
Developer of therapeutics for microbiome based diseases
Location
Watertown, United States
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Arranta Bio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Arranta Bio

Arranta Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, Aldevron, Kemwell Biopharma, Eurogentec and Ovagen, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of protein formulation, process & cell line development, and cGMP services
Locked Locked Locked
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
Locked Locked Locked
Integrated biologics development and manufacturing are provided as a CDMO.
Locked Locked Locked
Oligonucleotides, peptides, and antibodies are developed and manufactured by Eurogentec.
Locked Locked Locked
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
Locked Locked Locked
Precision fermentation services for biopharma and food are provided.
Premium access

Detailed competitors of Arranta Bio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Arranta Bio

Premium access

Complete news archive for Arranta Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Arranta Bio

Arranta Bio was founded in 2019.

Arranta Bio is headquartered in Watertown, United States.

Arranta Bio is a funded company, having raised a total of $82M across 1 funding round to date.

Arrantabio is a contract development and manufacturing organization focusing on the development of therapeutics for the treatment of human microbiome-related diseases. The company develops live biotherapeutic products through bacterial fermentation, isolation, drying, and encapsulation technologies for treating diseases associated with the human microbiome. It offers companies development and cGMP services such as cell banking, frozen blend, drug substance, primary packaging, analytical services and many more.

Arranta Bio's top competitors include KBI Biopharma, Aldevron and Ovagen.

Arranta Bio has made 1 acquisition, including Captozyme.

Arranta Bio has 3 investors. Key investors include Thermo Fisher Scientific, Recipharm, and Ampersand Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available